Opioid Overdose Risk in Cancer: New Cohort Findings
post on 18 Nov 2026
post on 18 Nov 2026
https://medicaltoxic.com/news/opioid-overdose-risk-cancer-patients

Opioid Overdose Risk in Cancer: New Cohort Findings
A study of more than 554,000 adults with solid tumors found opioid overdose uncommon overall, but more frequent with advanced cancer and higher-dose outpatient opioid prescribing.
A population-based study published in JAMA Network Open on November 10, 2026, found associations between opioid prescribing patterns and subsequent overdose among adults newly diagnosed with solid tumor cancers in Ontario, Canada. The findings support individualized safety monitoring, not blanket restrictions on cancer pain treatment. [1]
Researchers followed 554,316 adults diagnosed between 2013 and 2020, using linked provincial health records through December 31, 2024. During a median 5.5 years of follow-up, 1,591 patients (0.3%) had at least one nonfatal opioid overdose and 191 (0.03%) died from an opioid-involved overdose. These were recorded outcomes across the cohort, not events all proven to result from prescribed cancer analgesics. The nonfatal and fatal counts should not be added as if they represented mutually exclusive groups. [1]
The retrospective cohort included people with newly diagnosed solid tumors at multiple sites and stages. Prescription exposure was assessed from outpatient dispensing data, with dose and duration recalculated in successive 30-day intervals.
Researchers identified nonfatal overdoses through emergency-department visits or hospital admissions and fatal overdoses through linked death data. They then examined associations with cancer stage, opioid prescribing, prior opioid use disorder (OUD), symptom burden and other measured patient characteristics. [1]
This was not a randomized trial. The analyses cannot determine that an opioid prescription caused a particular overdose or that changing a prescription would necessarily have prevented it.
Although 425,254 patients (76.7%) received at least one outpatient opioid prescription during follow-up, serious overdose was uncommon. The study reported 53.9 nonfatal overdoses and 6.5 fatal overdoses per 100,000 person-years of observation. The corresponding cohort proportions were 0.3% and 0.03%, respectively. Patient percentages and rates per person-year measure different things and should not be interchanged. [1]
Nonfatal overdose was most frequent during the first year after diagnosis (107.3 per 100,000 person-years). Rates also differed by stage: 37.8 per 100,000 person-years in stage I versus 185.2 in stage IV. These stage-specific rates are descriptive associations, not the probability that an individual receiving an opioid will overdose.
During the first year, the hazard of any opioid overdose was higher for stage III than stage I cancer (HR 2.55; 95% CI 1.96–3.31) and higher still for stage IV (HR 6.24; 95% CI 4.68–8.31). These relative comparisons should be read alongside the low overall absolute event frequency. [1]
After adjustment for measured characteristics, an outpatient opioid prescription in the preceding 30 days was associated with a higher hazard of fatal or nonfatal overdose (adjusted HR 1.71; 95% CI 1.47–2.00) than no recent outpatient prescription.
For prescriptions meeting the study's high-dose definition of at least 50 mg morphine-equivalent daily dose (MEDD), the adjusted HR was 3.47 (95% CI 2.97–4.05). Each additional month of high-dose prescribing was associated with a further 3% relative increase in hazard (adjusted HR 1.03; 95% CI 1.03–1.04). [1]
The 50-mg MEDD value was an exposure category selected for analysis—not a validated cancer-pain dosing ceiling, automatic taper threshold or proof of causation. A hazard ratio also does not mean that 3.47% of recipients overdosed.
The observed association differed in analyses stratified by OUD history. A statistically nonsignificant additional association in patients with documented OUD must not be read as proof that these patients face no overdose risk or should be denied effective analgesia.
Higher cancer stage can coincide with more severe pain, complex symptoms, organ dysfunction, multiple medications and greater clinical need for opioids. These factors can influence both prescribing decisions and overdose risk.
The researchers adjusted for several measured characteristics, including prior OUD, prior overdose, symptom distress and reported function. Residual confounding remains possible, particularly when the clinical indication for an opioid and illness severity change over time. The data also could not cleanly distinguish the contribution of prescribed drugs from unregulated opioids in every overdose. [1]
The association should therefore inform risk awareness, not be used to blame patients or infer that appropriate pain treatment created all recorded harm.
In an accompanying JAMA Network Open commentary, Kurt Kroenke emphasized that serious overdoses were uncommon in this large cohort and that opioids still have an important role in cancer pain care. The findings favor individualized prescribing and closer monitoring for patients with greater risk rather than indiscriminate reduction of analgesia. [2]
The American Society of Clinical Oncology's cancer-pain guideline likewise supports offering opioids for moderate-to-severe cancer-related pain when not contraindicated, with treatment guided by acceptable relief, patient goals and monitoring for adverse effects. For patients with substance use disorders, it recommends collaboration with appropriate specialists. [3]
In practice, the research may prompt oncology, palliative-care and pharmacy teams to review sedation risk, interacting medicines, changing organ function, prior overdose and whether naloxone access or education is appropriate. Those decisions require individualized clinical judgment. The study does not justify abrupt opioid discontinuation, automatic dose cuts or withholding indicated analgesics.
For emergency assessment of established poisoning, MedicalToxic's Management of Acute Poisoning in the Intensive Care Unit remains the clinical-content owner; this News is not a new bedside management protocol.
Several limitations restrict causal and global interpretation. The cohort comes from Ontario, not all Canadian or international oncology populations. Exposure data covered outpatient prescriptions, not inpatient administration or every source of opioids. Coding and ascertainment may miss some overdoses, especially when sedation or respiratory changes overlap with advanced illness. Missing clinical details and unmeasured factors may affect the adjusted associations. [1]
The study did not randomize opioid doses, test a dose-reduction intervention or demonstrate that changing prescribing would improve mortality, pain control or quality of life. Neither its relative hazard estimates nor the 50-mg MEDD research threshold should be converted into a universal treatment rule.
Published November 10, 2026, the study adds a large, linked Ontario oncology cohort with both absolute overdose frequencies and time-updated prescribing associations. It identifies the early post-diagnosis period, advanced cancer and prolonged higher-dose prescribing as contexts warranting careful assessment, while explicitly showing that serious overdose was uncommon in the cohort.
This information complements—not replaces—existing clinical guidance. The central challenge is to reduce preventable overdose risk without undertreating cancer pain.
Among 554,316 Ontario adults with solid tumors, 0.3% experienced at least one recorded nonfatal opioid overdose and 0.03% had a fatal opioid overdose during follow-up. Higher cancer stage and higher-dose, longer-duration outpatient opioid prescribing were associated with increased hazards, but association is not proof that individual prescriptions caused overdoses.
The appropriate response is balanced, patient-centered medication safety: maintain effective cancer pain treatment, recognize periods of greater clinical complexity and assess overdose risk without imposing unvalidated dosing limits.
Marret, L., Gomes, T., Everett, K., Bagnarol, R., Zimmermann, C., & Lau, J. (2026). Opioid Use and Overdose in Patients With Solid Tumor Cancers. JAMA Network Open, 9(11), e2642997. https://doi.org/10.1001/jamanetworkopen.2026.42997.
Kroenke, K. (2026). Judicious Prescribing of Opioids in Patients With Cancer. JAMA Network Open, 9(11), e2643005. https://doi.org/10.1001/jamanetworkopen.2026.43005.
Paice, J. A., Bohlke, K., Barton, D., et al. (2023). Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline. Journal of Clinical Oncology, 41(4), 914–930. https://doi.org/10.1200/JCO.22.02198.
Keep reading